According to the Zhitong Finance App, TATA Health (01255) announced its 2026 interim results, with revenue of HK$47.275 million, a year-on-year decrease of 4.5%; loss attributable to company owners was HK$290,000, profit of HK$20.596 million for the same period last year; basic loss per share was HK$0.001.

Revenue declined year-on-year during the period, mainly due to a decrease in footwear business revenue in Hong Kong, China and Macau.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.